ClinicalTrials.gg
Active, not recruitingNCT05946941POETYK SjS-1Updated Apr 1, 2026

A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome

A Phase 3 interventional study of Deucravacitinib and Placebo in Sjögren's Syndrome, sponsored by Bristol-Myers Squibb. Active, not recruiting at 199 sites in 33 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-01.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
774
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 111 studies in Sjogren's Syndrome with a site in United States — 23 open to participants now, 29 under way, 8 of them phase 3. Sjogren's Syndrome · United States.

Enrollment
2nd of 76
774 · median 57
Started
2023
with 4 others
Phase 3
12 of 111
3 open now
Primary completion
2026-11
later than 4 of 27 live
Registered
88th of 111
by date
Lead sponsor
3 of 111
Bristol-Myers Squibb

Among the 111 studies in Sjogren's Syndrome with a site in United States, this one is the 2nd largest by enrollment of the 76 interventional ones that give a count, is one of 5 that started in 2023, is one of 12 in phase 3, reaches primary completion later than 4 of the 27 other live ones, and was the 88th registered.

Sjogren's Syndrome

330 studies on the registry are indexed under Sjogren's Syndrome; 99 are open to participants now.

Browse Sjogren's Syndrome studies →

Open to participants now

23 of the 111 studies in Sjogren's Syndrome with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 67 Sjogren's Syndrome studies recruiting now, 26 (39%) set no upper age limit and 25 (37%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies in Sjogren's Syndrome with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and efficacy of two doses of Deucravacitinib in adult participants with Active Sjögren's Syndrome.

03

Conditions studied

  • Sjögren's Syndrome

Browse trials for

Keywords

  • Deucravacitinib
  • Sjogren's Syndrome
  • BMS-986165
  • POETYK
  • Sjogren Syndrome
  • Sjogren-Larson Syndrome
  • Gougerot-Sjogren
  • Gougerot Sjogren Syndrome
  • Sjogren
  • Sjogren's
  • Sjogren Disease
  • Sjogren's Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Satisfy the 2016 American College of Rheumatology/European League Against Rheumatism criteria for the classification of SjS at screening (score ≥ 4), and who have disease duration (from time of initial clinical SjS diagnosis) of at least 16 weeks prior to screening.
  • Have moderate to severe SjS ESSDAI ≥ 5.
  • Short duration of disease (≤ 10 years) before screening.
  • A stimulated whole salivary flow (SWSF) ≥ 0.05 mililiters/minute (mL/minute).
  • Positive anti-Sjögren's syndrome-associated antigen A (anti-Ro/SSA) at screening.

Exclusion criteria

Exclusion Criteria

  • disease other than SjS (for example, rheumatoid arthritis, systemic lupus erthrematosus [SLE], systemic sclerosis).
  • Active fibromyalgia with pain symptoms or signs that would interfere with joint assessment or requiring adjustment in medication within the 3 months before screening to control symptoms; participants with fibromyalgia that is well controlled on stable treatment may otherwise be considered.
  • Medical condition associated with sicca syndrome.
  • Previous exposure to tyrosine kinase 2 (TYK2) inhibitors such as deucravacitinib or related compounds.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
774 participants (actual)

Study arms

  • Experimental
    Deucravacitinib, Dose 1

    Drug: Deucravacitinib

  • Experimental
    Deucravacitinib, Dose 2

    Drug: Deucravacitinib

  • Placebo comparator
    Placebo, followed by Deucravacitinib Dose 1 or Dose 2

    Drug: Deucravacitinib · Other: Placebo

Interventions

  • Specified dose on specified days

    Also known as: BMS-986165

  • OtherPlacebo

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Change from baseline in European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ESSDAI) Score at Week 52

    Time frame: Baseline, Week 52

Secondary outcomes

  1. Change from baseline in European League Against Rheumatism Sjögren's Syndrome Patient Reported Index (ESSPRI) Score at Week 52

    Time frame: Baseline, Week 52

  2. Number of participants with decrease in ESSPRI ≥ 1 or 15% from baseline at Week 52

    Time frame: Baseline, Week 52

  3. Number of participants with decrease in ESSDAI ≥ 3 points from baseline at Week 52

    Time frame: Baseline, Week 52

  4. Number of participants with ESSDAI < 5 at Week 52

    Time frame: Baseline, Week 52

  5. Change from baseline in ESSDAI at Week 24

    Time frame: Baseline, Week 24

  6. Change from baseline in stimulated whole salivary flow (SWSF) at Week 52

    Time frame: Baseline, Week 52

  7. Change from baseline in physician global assessment (PhGA) at Week 52

    Time frame: Baseline, Week 52

  8. Change from baseline in functional assessment of chronic illness therapy (FACIT)-fatigue at Week 52

    Time frame: Baseline, Week 52

  9. Change from baseline in ocular dryness numeric rating scale (NRS) at Week 52

    Time frame: Baseline, Week 52

  10. Change from baseline in oral dryness NRS at Week 52

    Time frame: Baseline, Week 52

  11. Change from baseline in joint/ muscle pain NRS at Week 52

    Time frame: Baseline, Week 52

  12. Number of participants with an increase of Schirmer's test ≥ 5 mm if abnormal baseline or no change of Schirmer's test to abnormal if baseline is normal

    Time frame: Baseline, Week 52

  13. Number of participants with adverse events (AEs)

    Time frame: Up to Week 160

  14. Number of participants with serious AEs (SAEs)

    Time frame: Up to Week 160

  15. Number of participants with AEs leading to discontinuation of treatment and study discontinuation

    Time frame: Up to Week 160

  16. Number of participants with AEs of special interest (AESIs)

    Time frame: Up to Week 160

  17. Number of participants with clinical laboratory abnormalities

    Time frame: Up to Week 160

  18. Number of participants with electrocardiogram (ECG) abnormalities

    Time frame: Up to Week 156

  19. Number of participants with vital sign abnormalities

    Time frame: Up to Week 160

07

Study locations

199 sites
  • Local Institution - 0228
    Fullerton, California 92835, United States
  • Local Institution - 0222
    La Palma, California 90623, United States
  • Local Institution - 0218
    San Francisco, California 94143, United States
  • Local Institution - 0203
    Santa Monica, California 90404, United States
  • Local Institution - 0067
    Denver, Colorado 80230, United States
  • Local Institution - 0049
    Clearwater, Florida 33765, United States
  • Local Institution - 0226
    Cooper City, Florida 33024, United States
  • Local Institution - 0223
    Sarasota, Florida 34239, United States
  • Local Institution - 0140
    Augusta, Georgia 30912, United States
  • Local Institution - 0229
    Lawrenceville, Georgia 30046, United States
  • Local Institution - 0174
    Skokie, Illinois 60076, United States
  • Local Institution - 0016
    Kansas City, Kansas 66160, United States
  • Local Institution - 0017
    Baton Rouge, Louisiana 70836, United States
  • Local Institution - 0125
    Monroe, Louisiana 71203, United States
  • Local Institution - 0187
    Baltimore, Maryland 21224-2746, United States
  • Local Institution - 0173
    Boston, Massachusetts 02111, United States
  • Local Institution - 0131
    Eagan, Minnesota 55123, United States
  • Local Institution - 0138
    Summit, New Jersey 07901, United States
  • Local Institution - 0009
    Albuquerque, New Mexico 87106, United States
  • Local Institution - 0184
    Mineola, New York 11501, United States
  • Local Institution - 0224
    Salisbury, North Carolina 28144, United States
  • Local Institution - 0130
    Duncansville, Pennsylvania 16635, United States
  • Local Institution - 0022
    Jackson, Tennessee 38305, United States
  • Local Institution - 0144
    Allen, Texas 75013, United States
  • Local Institution - 0227
    Katy, Texas 77494, United States
  • Local Institution - 0175
    Plano, Texas 75024, United States
  • Local Institution - 0133
    Seattle, Washington 98195, United States
  • Local Institution - 0189
    Spokane, Washington 99204, United States
  • Local Institution - 0050
    San Isidro, Alabama 1643, Argentina
  • Local Institution - 0100
    CABA, Buenos Aires 1114, Argentina
  • Local Institution - 0003
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1123AAO, Argentina
  • Local Institution - 0019
    Quilmes, Buenos Aires 1878, Argentina
  • Local Institution - 0026
    San Miguel de Tucumán, Tucumán Province 4000, Argentina
  • Local Institution - 0137
    CABA, 1405, Argentina
  • Local Institution - 0109
    City of Buenos Aires, 1425, Argentina
  • Local Institution - 0061
    Córdoba, X5004AUL, Argentina
  • Local Institution - 0120
    Woodville South, South Australia 5011, Australia
  • Local Institution - 0117
    Graz, A-8036, Austria
  • Local Institution - 0087
    Vienna, A-1180, Austria
  • Local Institution - 0172
    Ghent, 9000, Belgium
  • Local Institution - 0170
    Vitória, Espírito Santo 29041-295, Brazil
  • Local Institution - 0106
    Belo Horizonte, Minas Gerais 30130-100, Brazil
  • Local Institution - 0091
    Juiz de Fora, Minas Gerais 36010-570, Brazil
  • Local Institution - 0055
    Porto Alegre, Rio Grande do Sul 90560-030, Brazil
  • Local Institution - 0018
    São Paulo, São Paulo 04266-010, Brazil
  • Local Institution - 0111
    Uberlândia, 38405-320, Brazil
  • Local Institution - 0008
    Plovdiv, 4001, Bulgaria
  • Local Institution - 0221
    Sofia, 1618, Bulgaria
  • Local Institution - 0134
    Vancouver, British Columbia V5Z 1L7, Canada
  • Local Institution - 0063
    Toronto, Ontario M5T 2S8, Canada
  • Local Institution - 0004
    Sherbrooke, Quebec J1L 0H8, Canada
  • Local Institution - 0056
    Trois-Rivières, Quebec G8Z1Y2, Canada
  • Local Institution - 0136
    Santiago, Providencia 7501126, Chile
  • Local Institution - 0097
    Santiago, Santiago Metropolitan 7500710, Chile
  • Local Institution - 0015
    Santiago de Chlie, Santiago Metropolitan 8207257, Chile
  • Local Institution - 0032
    Viña del Mar, Valparaiso 2531172, Chile
  • Local Institution - 0216
    Santiago, 8350488, Chile
  • Local Institution - 0200
    Valdivia, 5110683, Chile
  • Local Institution - 0153
    Beijing, Beijing Municipality 100034, China
  • Local Institution - 0156
    Beijing, Beijing Municipality 100044, China
  • Local Institution - 0160
    Beijing, Beijing Municipality 100191, China
  • Local Institution - 0155
    Xiamen, Fujian 361003, China
  • Local Institution - 0095
    Guangzhou, Guangdong 510080, China
  • Local Institution - 0212
    Shenzhen, Guangdong 518020, China
  • Local Institution - 0214
    Zhengzhou, Henan 450052, China
  • Local Institution - 0149
    Wuhan, Hubei 430030, China
  • Local Institution - 0094
    Changsha, Hunan 410011, China
  • Local Institution - 0158
    Changsha, Hunan 410024, China
  • Local Institution - 0150
    Hohhot, Inner Mongolia 10000, China
  • Local Institution - 0215
    Nanjing, Jiangsu 210008, China
  • Local Institution - 0159
    Nanjing, Jiangsu 210029, China
  • Local Institution - 0154
    Suzhou, Jiangsu 215006, China
  • Local Institution - 0177
    Nanchang, Jiangxi 330006, China
  • Local Institution - 0213
    Nanchang, Jiangxi 330006, China
  • Local Institution - 0162
    Pingxiang, Jiangxi 337099, China
  • Local Institution - 0101
    Xi'an, Shaanxi 710061, China
  • Local Institution - 0182
    Taiyuan, Shan1xi 030032, China
  • Local Institution - 0102
    Shanghai, Shanghai Municipality 200000, China
  • Local Institution - 0151
    Shanghai, Shanghai Municipality 200065, China
  • Local Institution - 0157
    Shanghai Shi, Shanghai Sheng 200011, China
  • Local Institution - 0178
    Chengdu, Sichuan 610041, China
  • Local Institution - 0179
    Ürümqi, Xinjiang Sheng 830001, China
  • Local Institution - 0181
    Hangzhou, Zhejiang 310003, China
  • Local Institution - 0152
    Hangzhou, Zhejiang 314408, China
  • Local Institution - 0161
    Ningbo, Zhejiang 315010, China
  • Local Institution - 0093
    Wenzhou, Zhejiang 325000, China
  • Local Institution - 0168
    Barranquilla, Atlántico 080003, Colombia
  • Local Institution - 0043
    Chía, Cundinamarca 250001, Colombia
  • Local Institution - 0037
    Bogota D.C, 110221, Colombia
  • Local Institution - 0199
    Helsinki, 00290, Finland
  • Local Institution - 0135
    Kuopio, 70100, Finland
  • Local Institution - 0119
    Turku, 20520, Finland
  • Local Institution - 0005
    Amiens, 80054, France
  • Local Institution - 0073
    Bordeaux, 33075, France
  • Local Institution - 0070
    Grenoble, 38043, France
  • Local Institution - 0074
    Le Havre, 76083, France
  • Local Institution - 0167
    Le Kremlin-Bictre, 94270, France
  • Local Institution - 0025
    Paris, 75012, France
  • Local Institution - 0107
    Paris, 75014, France
  • Local Institution - 0057
    Paris, 75651, France

Showing the first 100 of 199 sites across 33 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2023 (actual). Primary completion is estimated for Nov 2026, 38 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2023
First posted
Jul 14, 2023
StartActual
Sep 11, 2023
Primary completionEst.
Nov 18, 2026
CompletionEst.
Nov 16, 2028
Last update
Apr 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05946941
Responsible party
Sponsor
First posted
Jul 14, 2023
Start date
Sep 11, 2023
Primary completion
Nov 18, 2026 (estimated)
Completion
Nov 16, 2028 (estimated)
Last update
Apr 1, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deucravacitinib

Start the discussion